Welcome to RXI!

Content & Disclosure

 

Charts & Data

Resources

 

You are here: Home » REGULAR CONTENT (New)

Articles, Alerts & Updates

Regular Content

 

 

New to RXI? 

Take a minute to review this brief outline.

 

ARTICLES, ALERTS, AND UPDATES

  My Call on Innophos X2
  My Call on KMGB
  Advances in Hand Surgery
  Sell BioScrip
  Justin M. Hall's Call on Response Genetics
  Justin M. Hall's Call on Gold
  Immunogen's T-DM1 Delayed
  Justin M. Hall's Call on Cereplast
  Epicept Likely to Succeed with Regulatory Challenge
  BioScrip Continues to Advance
  FDA Crushes Epicept
  Epicept Advancing in Front of Priority Review
  Justin M. Hall's Call on Jazz Pharma (PDF)
  Ground Zero Mosque
  Will You Buy GM at IPO?
  OxiGene Jumps 30%+
  Member Earns 200% Gain on Cypress Biosciences
  BioScrip Sell-Off
  Member Feedback
  Change Coming to US Healthcare
  Cypress Biosciences (CYPB)
  A Doc’s Take on Oxigene’s Zybrestat Ophthalmology Program
  Oxigene: Dirt Cheap, Lots of Potential
  8 STRONG BUYS
  Independence Day 2010
  Persist Until You Succeed
  Spectrum Pharma: Looking Ahead at Continued Growth
  A Hidden Biotech Buy
  Infinity Pharma: A Promising, Underappreciated Cancer Drug Maker
  Orange County Business Journal
  Three Underappreciated Cancer Drug Makers
  Spectrum Pharma: Additional Trial Not Required
  December's Game Plan for Biotech
  Spectrum Pharma: Zevalin Sales Ramp Up
  Spectrum Pharma: CMS Rules in Favor of Zevalin
  Spectrum Pharma: Zevalin Has Blockbuster Potential
  On Small Cap Drug Makers and Volatility
  Spectrum Pharma: Undervalued and (Now) Oversold
  How Zevalin Is Helping Spectrum
  Spectrum Pharma: Despite Share Offering, Still Cheap vs. Other Cancer Drug Makers
  Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up
  Five Drug Makers with Pending Catalysts
  SmartHeat: An Emerging Market Clean Energy Growth Play
  Lucky 13 Portfolio: Fuel Systems & Three Cancer Drug Makers
  Spectrum Pharma: The Labor Day Catalyst
  Ariad Pharma: Significant Catalysts Approaching
  Spectrum Pharma: Rumors of Buyout Talks Persist
  These Small Cap Cancer Drugmakers Have Big Growth Potential
  Spectrum Pharma: Potential Acquisition Target
  Ariad Pharma: Advancing in Front of Interim Phase 3 Results
  Spectrum Pharma: Outlook Remains Very Promising
  Spectrum Pharma: Zevalin and the Importance of Approval
  Spectrum Pharma: Oversold and Undervalued
  Spectrum Pharma: Temporary Setback
  17 Reasons Why Bayer Might Acquire Spectrum Pharma
  Spectrum Pharma: Optimistic About Zevalin's Prospects
  Spectrum Pharma: Undervalued Growth Company with Strong Late-Stage Pipeline
  Two Possible Approvals for Spectrum Pharmaceuticals